Clinical Trial

First in Human Pilot Study to Assess the Safety and Efficacy of Dendritic Cells Loaded With Frameshift Derived Neopeptides for the Prevention of Cancer in of Lynch Syndrome Carriers

Study acronym: DELAY
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Tha aim of this clinical trial is to evaluate safety and tolerability of autologous peripheral blood differentiated and matured adult dendritic cells. Immunogenicity of the prduct(DC-DELAY) will be evaluated also.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-01; most recent amendment 2026-04-10.
Status change: Not Yet Recruiting → Recruiting 2025-11-26
Trial Details
NCT Number NCT07163403
Lead Sponsor Fundacion Clinic per a la Recerca Biomédica
Conditions Lynch Syndrome
Enrollment 20 participants
Start Date 2025-09-04
Primary Completion 2028-09-20 (estimated)
Study Completion 2028-09-20 (estimated)
Updated on ClinicalTrials.gov 2026-04-13